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Abstract
Background: Acute chest pain is responsible for approximately 700,000 patient attendances per
year at emergency departments in England and Wales. A single centre study of selected patients
suggested that chest pain unit (CPU) care could be less costly and more effective than routine care
for these patients, although a more recent multi-centre study cast doubt on the generalisability of
these findings.
Methods: Our economic evaluation involved modelling data from the ESCAPE multi-centre trial
along with data from other sources to estimate the comparative costs and effects of CPU versus
routine care. Cost effectiveness ratios (cost per QALY) were generated from our model.
Results: We found that CPU compared to routine care resulted in a non-significant increase in
effectiveness of 0.0075 QALYs per patient and a non-significant cost decrease of £32 per patient
and thus a negative incremental cost effectiveness ratio. If we are willing to pay £20,000 for an
additional QALY then there is a 70% probability that CPU care will be considered cost-effective.
Conclusion: Our analysis shows that CPU care is likely to be slightly more effective and less
expensive than routine care, however, these estimates are surrounded by a substantial amount of
uncertainty. We cannot reliably conclude that establishing CPU care will represent a cost-effective
use of health service resources given the substantial amount of investment it would require.
Background
Acute chest pain is responsible for approximately 700,000
patient attendances per year at emergency departments in
England and Wales and 20–30% of emergency medical
admissions [1]. The Chest Pain Unit (CPU) has been
developed to improve care and reduce costs for patients
with acute chest pain. A single centre study [2] has shown
that CPUs care can reduce admissions, reattendances and
outpatient follow-up, and improve quality of life for
selected low-risk patients who are suitable for CPU care.
The ESCAPE (Effectiveness and Safety of Chest pain
Assessment to Prevent Emergency admissions) multicen-
tre trial was undertaken to determine whether CPU could
reduce admissions, improve outcomes and be cost effec-
tive across a variety of NHS hospitals. The main analysis
from the ESCAPE multicentre trial [3] showed that the
introduction of CPU care across a range of hospitals: 1)
Did not alter the proportion of patients admitted, 2) Was
associated with increased reattendances and subsequent
admissions and 3) May have been associated with
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increased numbers of patients attending with chest pain.
It concluded that establishing CPU care throughout the
NHS could not be justified on the basis of any expectation
of reducing emergency admissions.
Even if CPU care does not reduce hospital admissions it
may still be cost-effective, compared to routine care, if it
improves patient outcomes or reduces health service costs
in other ways, such as by reducing length of hospital stay.
We therefore planned to undertake an economic evalua-
tion alongside the ESCAPE multicentre trial [3], using
data from the trial and from external sources in a decision-
analytic model (the rationale for using this type of model
is explained in a later section). Our specific objective was
to estimate the cost-effectiveness of CPU, compared to
routine care, in terms of the incremental cost per quality
adjusted life year (QALY) gained. This outcome measure
allows us to combine length of life and quality of life into
a single summary measure and thus allows a multidimen-
sional comparison of CPU care with routine care.
Methods
We developed a decision-analytic model to estimate the
costs and QALYs accrued by patients with chest pain who
received CPU or routine care. We assumed that CPU care
could potentially influence QALYs in three ways: 1)
Reducing the time delay to reperfusion for ST-elevation
myocardial infarction; 2) Reducing the proportion of
patients inadvertently discharged home with acute coro-
nary syndrome; and 3) Reducing diagnostic uncertainty
and thus improving quality of life.
Data Sources
Cost and effectiveness data were split into two categories,
short term or costs and effects up to 6 months, and long
term or lifetime costs and effects. The economic analysis
primarily used data from the ESCAPE study that provided
the data for the 6 month costs and effects. This study was
a cluster randomised controlled trial involving 14 hospi-
tals – half of which implemented the CPU protocol whilst
the rest provided routine care. All 14 hospitals in the pre-
intervention phase provided routine care (year 1 – T1).
Seven out of these were randomly selected to provide CPU
care in the post-intervention phase (year 2 – T2) whilst the
rest continued to provide routine care. Cost and effective-
ness (EQ-5D) data were collected up to six months after
initial hospital attendance using postal questionnaires
mailed to a subgroup of 200 patients with chest pain
before and after intervention at each hospital. Computer
records were also used where appropriate to measure
resource use for these patients (full details of the ESCAPE
study have been reported elsewhere [3]).
Short term cost and effectiveness data
The following items of resource use were identified in the
ESCAPE study:
1. Initial emergency department attendance, CPU care,
and hospital admission.
2. Emergency department re-attendances, hospital
(re)admissions, outpatient visits, diagnostic tests, opera-
tions and procedures.
3. Telephone health advice.
4. GP, nurse and social work visits.
Resource items were valued using national unit costs for
2005/2006 [4,5]. Total costs were then aggregated across
patients to derive a total cost per patient up to six months.
This included the additional cost of providing CPU care
for all post-intervention patients attending a CPU hospi-
tal.
EQ-5D data from the ESCAPE study at one and six months
was used to estimate the area under the curve for health
utility. Data from all patients who attended a hospital
without an active CPU (i.e. pre-intervention at CPU hos-
pitals and both time periods at control hospitals) were
used to estimate QALYs up to six months. Area under the
curve data for health utility were analysed using a random
effects regression model to estimate the absolute effect of
availability of CPU care upon QALYs up to six months,
compared to control hospitals, adjusted for baseline dif-
ferences, age and gender.
Long term cost and effectiveness data
Long-term cost and effectiveness data for survivors with
coronary heart disease were estimated from an external
data source [6]. We used the same values for all patients
(regardless of the underlying cause of their chest pain),
because only those with myocardial infarction or ACS
could potentially suffer mortality that would lead to a dif-
ference between the two strategies (CPU or routine care).
Other data sources
We estimated the expected mortality from ST-elevation
myocardial infarction using time delay data from the
ESCAPE trial and an analysis by Boersma [7] that used
data from thrombolytic trial data to estimate the relation-
ship between time delay from symptom onset to throm-
bolysis and expected probability of mortality for a typical
patient. The Boersma equation was used to calculate
expected mortality, according to their symptom onset to
needle time, for all patients thrombolysed for ST-eleva-
tion myocardial infarction in the study. Data from
patients attending a hospital with no active CPU (i.e. pre-BMC Health Services Research 2008, 8:174 http://www.biomedcentral.com/1472-6963/8/174
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intervention at CPU hospitals and both time periods at
control hospitals) were used to estimate the mortality of
ST-elevation myocardial infarction when no CPU is avail-
able. For the effect of CPU care upon mortality from ST-
elevation myocardial infarction expected mortality data
was used, calculated using the Boersma equation, to esti-
mate the absolute effect of CPU care upon mortality. A
random effects model was used to estimate the effect of
CPU care compared to control hospitals, after adjusting
for baseline difference between CPU and control hospi-
tals.
In order to the estimate the effect of CPU availability upon
discharge with ACS we identified all study patients who
were discharged after initially attending with chest pain
and then were re-admitted within 30 days with a com-
plaint that was not obviously unrelated to chest pain. Ran-
dom effects modelling was used to estimate the effect of
CPU availability upon this outcome, compared to control
hospitals. Adjustments were made for baseline differences
between CPU and routine care in terms of age and gender.
It was assumed that the relative effect of CPU availability
upon this outcome was equivalent to the effect of CPU
availability upon discharge with ACS. The rate of dis-
charge with ACS at hospitals without a CPU was estimated
using data from a study by Collinson et al [8] who fol-
lowed up a cohort of patients with chest pain who were
discharged after emergency department assessment.
Table 1 shows the parameters used to populate our model
which also includes the data from external sources used in
our analysis [6,8,9].
Economic analysis
We developed a decision analytic model (the particular
model used in this paper is a decision tree) to estimate the
costs and QALYs of a population of patients attending an
emergency department with acute chest pain. The model
compared costs and QALYs accrued by providing CPU
care to costs and QALYs accrued by providing routine care,
in order to estimate the incremental cost per QALY gained
by CPU care.
Table 1: Model parameter descriptions and values
Parameter Description Source Distributions
Beta Distribution
Mean Alpha (Beta)
pSTEMI Probability of chest pain patients with ST-
elevation myocardial infarction
Trial data: audited patients with ST-elevation 
myocardial infarction/all patients with chest pain
0.036 4800 (130000)
pACSdisc Probability of being discharged with ACS at a 
hospital with no CPU
External data [8] 0.012 7.55 (621.82)
Incmort Probability of inadvertent discharge upon ACS 
mortality, compared to admission
External data [9] 0.03 10.92 (353.1)
Normal Distribution
Mean Standard Error
mortSTEMI Mortality of ST-elevation myocardial infarction at 
hospitals with no CPU
Modelled from trial onset to needle time data using 
Boersma equation [7]
0.1003 0.0004
CPUdisc Effect of CPU availability upon probability of 
being discharged with ACS
Trial data: effect of CPU upon (re)admission of initially 
discharged chest pain patients
1.256 0.1962
cpu_STEMI CPU availability impact upon mortality from ST-
elevation myocardial infarction
Modelled from trial onset to needle time data using 
Boersma equation
0.0007 0.0013
routQALY QALYs accrued up to six months after initial 
attendance at a hospital with no CPU
Trial data: Area under the curve for health utility for all 
patients attending a hospital with no active CPU
0.318 0.0038
cpuQALY Effect of CPU availability upon QALYs accrued 
up to six months after initial attendance
Trial data: Effect of CPU availability upon area under 
the curve for health utility
0.0084 0.0129
ltQALY Lifetime QALYs accrued by a typical patient with 
coronary heart disease
External data: Vergel et al [6] 6.829 0.3401
routCOST Costs up to six months after initial attendance at 
a hospital with no CPU
Trial data: Mean cost per patient for all attending a 
hospital with no CPU
2405 63.5216
cpuCOST Effect of CPU availability upon costs up to six 
months after initial attendance
Trial data: Effect of CPU availability upon mean cost per 
patient
-31 219.647
ltCOST Lifetime costs of care for a typical patient with 
coronary heart disease
External data: Vergel et al [6] 10,079 2200BMC Health Services Research 2008, 8:174 http://www.biomedcentral.com/1472-6963/8/174
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Decision analysis modelling was used because it allows us
to estimate how a number of different potential effects of
CPU care may influence a common outcome (QALYs). It
also allows us to estimate the overall effect of CPU care in
a way that can be compared with the effect of other health
care interventions aimed at other conditions.
Probabilistic Sensitivity analysis (PSA)
Costs and outcomes were modelled using the decision
tree outlined in Figure 1 to estimate the incremental cost
per QALY gained. We undertook probabilistic sensitivity
analysis (PSA) modelling, using Microsoft Excel. PSA is a
widely used technique that allows estimation of the effect
of varying model parameters in order to take account of
the uncertainty in the parameter estimates that inform our
cost effectiveness model. Each of the parameters we use in
our model has been estimated with a degree of uncer-
tainty and thus there is a need to spread joint parameter
uncertainty to reflect the decision uncertainty. As our
model is non linear the use of PSA provides the only unbi-
ased estimate of mean cost effectiveness. Finally, the
model assumes that there are no limitations in capacity,
such as the availability of hospital beds and staff. How-
ever, because of the timeframe of our analysis, we feel that
this is not an unrealistic assumption.
The Decision Tree
The decision tree outlined in Figure 1 was constructed to
allow comparison of a decision to manage patients with a
CPU or to use routine care. With each strategy (CPU or
routine care) patients could follow one of three pathways.
1) A proportion of patients will have a ST-elevation myo-
cardial infarction (pSTEMI) and will be eligible for throm-
bolysis. This proportion does not depend upon whether
the hospital has a CPU or not, but may vary between indi-
vidual hospitals. Of these individuals a proportion of
thrombolysed patients will die within 30 days (mort-
STEMI). This proportion will depend upon whether the
hospital has a CPU and whether CPU care affects time
delays to thrombolysis (cpu_mortSTEMI). 2) A propor-
tion of patients with chest pain will have ACS and be inad-
vertently discharged without treatment (pACSdisc) [8].
This proportion will depend upon whether the hospital
has a CPU and whether CPU care affects the probability of
inadvertent discharge with ACS (CPUdisc). Patients who
are discharged with ACS will have an increased probabil-
ity of dying (Incmort), compared to those who are not dis-
charged [10]. This increased probability of dying is not
dependent upon CPU care and does not vary between
hospitals. 3) All other patients who do not die and do not
go through the first two pathways will have quality of life
over the next six months determined by whether they
The ESCAPE decision tree comparing costs and outcomes of CPU to routine care Figure 1
The ESCAPE decision tree comparing costs and outcomes of CPU to routine care.BMC Health Services Research 2008, 8:174 http://www.biomedcentral.com/1472-6963/8/174
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attended a hospital with CPU care (cpuQALY) or not
(routQALY).
Resource use costs up to 6 months after original attend-
ance are reflected in the parameters routCOST, while cpu-
COST reflects the effect of CPU availability upon costs
over this time period.
We applied a beta distribution to the following probabil-
ities p_STEMI, pACSdisc and Incmort and a normal distri-
bution to the rest of the parameters (see Table 1). Monte
Carlo simulation was used to sample from each inde-
pendent parameter distribution and calculate the costs
and outcomes associated with each strategy, running 1000
replications of the model.
Model Assumptions
We assumed that CPU care could influence health service
costs up to six months after attendance, and costs thereaf-
ter would be determined by whether the patient survived
or not. We assumed that CPU care could influence out-
comes in three possible ways:
1. Reducing death from myocardial infarction by reducing
time to thrombolysis for patients with ST-elevation myo-
cardial infarction (STEMI)
2. Reducing death from acute coronary syndrome (ACS)
by reducing the proportion of patients discharged with
ACS (inappropriate discharge)
3. Improving quality of life for all patients by providing a
more rigorous diagnostic assessment
For all three pathways, after six months survival, we
assume that quality of life and resource use will be inde-
pendent of care initially received (ltQALY and ltCOST
respectively). We also assumed that deaths due to other
causes would not be influenced by the care initially
received.
Results
The values used to populate the economic model were:
1. The proportion of chest pain patients who had ST-ele-
vation myocardial infarction varied across the trial hospi-
tals from 1.6 to 7.8% with an overall mean value of 3.6%
(95% CI 3.5 to 3.7).
2. Mean expected mortality among patients with ST-eleva-
tion myocardial infarction was 10.03% (95% CI 9.96 to
10.10) among patients who attended when no CPU was
available.
3. The estimated effect of CPU availability upon expected
mortality from ST-elevation myocardial infarction was a
non-significant increase of 0.07% (95% CI -0.18 to 0.33).
4. The proportion of chest pain patients subsequently dis-
charged with ACS at a hospital with no CPU was esti-
mated to be 1.2% (95% CI 0.6 to 2.3) [8].
5. The odds ratio for the adjusted effect of CPU care upon
the proportion of patients who were discharged and then
subsequently admitted was 1.26 (95% CI 0.92 to 1.72; p
= 0.146), giving a relative risk of 1.256 (95% CI 0.921 to
1.705).
6. The effect of inadvertent discharge upon mortality from
ACS, compared to admission was estimated to be a 3%
absolute increase using data from a literature review out-
lined in our previous model [9].
7. The mean area under the curve for health utility up to
six months after attending a hospital with no CPU availa-
ble was estimated to be 0.318 QALYs (95% CI 0.311 to
0.326) using trial data from patients attending CPU hos-
pitals before intervention and attending a control hospital
at any time.
8. The estimated effect of CPU upon mean area under the
curve for health utility up to six months was a non-signif-
icant improvement of 0.0084 (95% CI -0.0168 to 0.0337;
p = 0.512).
9. Discounted quality-adjusted life expectancy (after the
initial six months) for patients with coronary heart disease
was estimated to be 6.83 QALYs [6].
Costs per patient up to six months ranged from zero to
£28,248, with a mean of £2385 and a median of £1566.
Mean cost per patient was £2468 before and £2326 after
intervention at the CPU hospitals, and was £2417 before
and £2330 after intervention at the control hospitals. The
mean cost per patient for all patients who attended a hos-
pital with no CPU (i.e. all patients at control hospitals and
pre-intervention patients at CPU hospitals) was £2405
(95% CI 2280 to 2529). The introduction of CPU care was
associated with a non-significant £31 per patient reduc-
tion in 6-month costs (95% CI -400 to 461, p = 0.889).
Cost effectiveness ratios
The model showed that CPU care was associated with a
small non significant increase in effectiveness of 0.0075
QALYs per patient (95% CI -0.0168 to 0.0331), and non
significant decrease in costs of £32 per patient (95% CI -
480.41 to 399.86). Hence, inclusion of costs beyond six
months had only a small effect on the estimated cost dif-BMC Health Services Research 2008, 8:174 http://www.biomedcentral.com/1472-6963/8/174
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ferences between strategies (routine or CPU care). CPU
care therefore dominates in the base case analysis.
Figure 2 shows the cost-effectiveness plane for CPU com-
pared to routine care. This is a plot of the results of the PSA
(for 1000 replications of the model) showing the differ-
ence in effectiveness (X-axis) and costs (Y-axis) between
CPU and routine care. Each point provides an estimate of
whether CPU is cost-effective compared to routine care:
408 of the estimates lie in the south-east quadrant (CPU
dominates routine care), 314 lie in the north-east quad-
rant (CPU more effective but more expensive), 152 lie in
the south-west quadrant (CPU cheaper but less effective)
and 126 lie in the north-west quadrant (routine care dom-
inates). Although the baseline estimates suggest that CPU
dominates routine care, this highlights the substantial
uncertainty around this point estimate, as the predicted
estimates fall in all four quadrants of the cost-effectiveness
plane.
Figure 3 shows the cost-effectiveness acceptability curve
for CPU compared to routine care. This shows the proba-
bility that CPU will be considered cost-effective plotted
against the threshold for willingness to pay per QALY
gained, ranging from zero to £100,000 per QALY. If we are
not willing to pay anything to gain additional QALYs,
CPU care is still slightly more likely to be cost-effective
than routine care (about 56% that CPU care is less costly
than routine care). At a willingness to pay threshold of
£20,000 for an additional QALY then the probability that
CPU care will be considered cost-effective rises to about
70%. No matter how much we are willing to pay the prob-
ability of CPU care being cost-effective does not reach
75%.
Discussion
We found that on average CPU care would result in a cost
saving compared to routine care, although this was not a
statistically significant result. The probability that CPU
care is cost effective is approximately 70% at a willingness
to pay threshold of £20,000 per QALY. This finding, how-
ever, is subject to uncertainty and it is necessary to bear in
mind the substantial investment that would be needed to
provide CPU care throughout the NHS. On the basis of
this analysis we cannot justify widespread implementa-
tion of CPU care throughout the NHS.
Most previous cost-effectiveness analyses of CPU care
originate from the United States (Roberts, Farkouh,
Gomez [11-13]). These studies were based on randomised
Cost-effectiveness plane for CPU compared to routine care Figure 2
Cost-effectiveness plane for CPU compared to routine care.
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trials comparing CPU care to inpatient care that primarily
compared resource use and did not evaluate patient-cen-
tred outcomes. They showed that CPU care was cheaper
than routine care, but it is not clear whether this finding
can be extrapolated outside the United States. It is also
only relevant if CPU care replaces inpatient care. Although
practice in the UK has changed recently, with increasing
use of percutaneous coronary intervention, the findings of
the ESCAPE trial [14] suggest that many patients with
chest pain still do not receive inpatient care.
One previous cost-effectiveness analysis in the UK, based
on a single-centre randomised trial [2], showed a signifi-
cant improvement in QALYs and a non-significant reduc-
tion in costs among selected low risk patients who were
deemed suitable for CPU care. These findings were not
fully reproduced in the ESCAPE trial. Both the QALY gain
and cost reduction associated with CPU care were smaller
than in the single-centre trial and were non-significant.
This is presumably because the ESCAPE multicentre trial
evaluated the effect of CPU care across all patients with
chest pain, rather than selected low-risk patients. The
effect of CPU care may therefore have been lost amongst
the overall population with chest pain or balanced by neg-
ative effects from implementing CPU care upon patients
who attended CPU hospitals with chest pain but did not
receive CPU care.
This economic analysis has an important limitation that
needs to be taken into account in interpreting the find-
ings. The comparison of the costs and effects of CPU ver-
sus routine care is made on a per patient basis, which
assumes that CPU and routine care will be applied to the
same population of patients attending hospital. In other
words, it assumes that the decision to implement CPU
care or continue with routine care does not influence the
size or characteristics of the population requiring the serv-
ices. However, it has been reported elsewhere [14] that the
implementation of CPU care may be associated with
increased attendances with chest pain and increased med-
ical admissions. If introducing CPU care leads to
increased attendances with chest pain then the assump-
tions in this analysis will not hold. Furthermore, whereas
it is clear that additional attendances will incur health
service costs, we do not have any evidence that they will
gain benefit from their attendance.
Thus evidence, which cannot be incorporated in the eco-
nomic model, leads us to believe that introducing CPU
care may increase health service costs without any corre-
Cost-effectiveness acceptability curve for CPU compared to routine care Figure 3
Cost-effectiveness acceptability curve for CPU compared to routine care.
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sponding evidence that it will improve outcomes. In these
circumstances it is difficult to claim that CPU is likely to
be cost-effective, especially considering the substantial
uncertainty surrounding the results on the economic anal-
ysis.
Another limitation is that there was considerable varia-
tion in outcomes between the individual hospitals
involved in the ESCAPE trial and in the effect of introduc-
ing CPU care at individual CPU hospitals. We therefore
cannot exclude the possibility that individual CPUs can
markedly reduce costs and improve outcomes. Indeed, the
previous single centre study [2] showed that an active
CPU can improve outcomes and possibly reduce costs
among selected patients. However, we can reasonably
conclude that widespread implementation of CPU care is
unlikely to represent a cost-effective use of health service
resources.
We recently surveyed the development of chest pain serv-
ices in the UK [15] and found that formal development of
CPU care was limited and mostly restricted to within tri-
als, although there was substantial informal and ad hoc
development of acute chest pain services. The findings of
our analysis and the ESCAPE multi-centre trial suggest
that this progress is probably appropriate and that invest-
ment in formal development of CPU care throughout the
UK would be misplaced.
Conclusion
We found that introducing CPU care had no statistically
significant effect on either costs or outcomes compared to
routine care. Our findings are highlighted by the fact that
the predicted estimates fall in all four quadrants of the
cost effectiveness plane. These results do not support the
widespread implementation of CPU care.
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